ATC code J: Antiinfectives for systemic use |
---|
|
Human only |
ATCvet only |
|
Other ATC codes |
ATC code J Antiinfectives for systemic use is a section of the Anatomical Therapeutic Chemical Classification System, a system of alphanumeric codes developed by the World Health Organization (WHO) for the classification of drugs and other medical products. [1] [2] [3] [4]
Codes for
veterinary use (
ATCvet codes) can be created by placing the letter Q in front of the human ATC code: for example, QJ.
[5] ATCvet codes without corresponding human ATC codes are cited with the leading Q in the following list.
National issues of the ATC classification may include additional codes not present in this list, which follows the WHO version.
Major chemical drug groups – based upon the
Anatomical Therapeutic Chemical Classification System | |
---|---|
gastrointestinal tract / metabolism ( A) | |
blood and blood forming organs ( B) | |
cardiovascular system ( C) | |
skin ( D) | |
genitourinary system ( G) | |
endocrine system ( H) | |
infections and infestations ( J, P, QI) | |
malignant disease ( L01–L02) | |
immune disease ( L03–L04) | |
muscles,
bones, and joints ( M) | |
brain and nervous system ( N) |
|
respiratory system ( R) | |
sensory organs ( S) | |
other ATC ( V) | |
30S |
| ||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
50S | |||||||||||||||
EF-G |
| ||||||||||||||
|
Beta-lactams (inhibit synthesis of peptidoglycan layer of bacterial cell wall by binding to and inhibiting PBPs, a group of D-alanyl-D-alanine transpeptidases) |
| ||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Polypeptides |
| ||||||||||||||||||||||||||||||||||||||||||
Intracellular |
| ||||||||||||||||||||||||||||||||||||||||||
Other |
| ||||||||||||||||||||||||||||||||||||||||||
|
Antifolates (inhibit bacterial purine metabolism, thereby inhibiting DNA and RNA synthesis) |
| ||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Quinolones (inhibit bacterial topoisomerase and/or DNA gyrase, thereby inhibiting DNA replication) |
| ||||||||||||||||
Anaerobic DNA inhibitors |
| ||||||||||||||||
RNA synthesis |
| ||||||||||||||||
|
Other/ungrouped |
---|
Wall/ membrane |
| ||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Intracellular |
| ||||||||||||||||||||||
Others |
| ||||||||||||||||||||||
|
Nucleic acid inhibitor |
| ||||||||
---|---|---|---|---|---|---|---|---|---|
Protein synthesis inhibitor |
| ||||||||
Cell envelope antibiotic |
| ||||||||
Other/unknown | |||||||||
Combinations | |||||||||
|
Baltimore I |
| ||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Hepatitis B (VII) | |||||||||||||||||||||
Multiple/general |
| ||||||||||||||||||||
|
Hepatitis C |
| ||||||||
---|---|---|---|---|---|---|---|---|---|
Hepatitis D | |||||||||
Picornavirus | |||||||||
Anti- influenza agents | |||||||||
Multiple/general |
| ||||||||
|
Capsid inhibitors | |||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Entry/fusion inhibitors ( Discovery and development) | |||||||||||||
Integrase inhibitors (Integrase strand transfer inhibitors (INSTI)) | |||||||||||||
Maturation inhibitors | |||||||||||||
Protease Inhibitors (PI) ( Discovery and development) |
| ||||||||||||
Reverse-transcriptase inhibitors (RTIs) |
| ||||||||||||
Combined formulations |
| ||||||||||||
Pharmacokinetic boosters | |||||||||||||
Experimental agents |
| ||||||||||||
|
Immune sera and immunoglobulins (
J06) | |||||
---|---|---|---|---|---|
Polyclonal antibodies |
| ||||
Monoclonal antibodies |
Development | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Classes | |||||||||||
Administration | |||||||||||
Vaccines |
| ||||||||||
Inventors/ researchers | |||||||||||
Controversy | |||||||||||
Related | |||||||||||
|
ATC code J: Antiinfectives for systemic use |
---|
|
Human only |
ATCvet only |
|
Other ATC codes |
ATC code J Antiinfectives for systemic use is a section of the Anatomical Therapeutic Chemical Classification System, a system of alphanumeric codes developed by the World Health Organization (WHO) for the classification of drugs and other medical products. [1] [2] [3] [4]
Codes for
veterinary use (
ATCvet codes) can be created by placing the letter Q in front of the human ATC code: for example, QJ.
[5] ATCvet codes without corresponding human ATC codes are cited with the leading Q in the following list.
National issues of the ATC classification may include additional codes not present in this list, which follows the WHO version.
Major chemical drug groups – based upon the
Anatomical Therapeutic Chemical Classification System | |
---|---|
gastrointestinal tract / metabolism ( A) | |
blood and blood forming organs ( B) | |
cardiovascular system ( C) | |
skin ( D) | |
genitourinary system ( G) | |
endocrine system ( H) | |
infections and infestations ( J, P, QI) | |
malignant disease ( L01–L02) | |
immune disease ( L03–L04) | |
muscles,
bones, and joints ( M) | |
brain and nervous system ( N) |
|
respiratory system ( R) | |
sensory organs ( S) | |
other ATC ( V) | |
30S |
| ||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
50S |
| ||||||||||||||||||
EF-G |
| ||||||||||||||||||
|
Beta-lactams (inhibit synthesis of peptidoglycan layer of bacterial cell wall by binding to and inhibiting PBPs, a group of D-alanyl-D-alanine transpeptidases) |
| ||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Polypeptides |
| ||||||||||||||||||||||||||||||||||||||||||
Intracellular |
| ||||||||||||||||||||||||||||||||||||||||||
Other |
| ||||||||||||||||||||||||||||||||||||||||||
|
Antifolates (inhibit bacterial purine metabolism, thereby inhibiting DNA and RNA synthesis) |
| ||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Quinolones (inhibit bacterial topoisomerase and/or DNA gyrase, thereby inhibiting DNA replication) |
| ||||||||||||||||
Anaerobic DNA inhibitors |
| ||||||||||||||||
RNA synthesis |
| ||||||||||||||||
|
Other/ungrouped |
---|
Wall/ membrane |
| ||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Intracellular |
| ||||||||||||||||||||||
Others |
| ||||||||||||||||||||||
|
Nucleic acid inhibitor |
| ||||||||
---|---|---|---|---|---|---|---|---|---|
Protein synthesis inhibitor |
| ||||||||
Cell envelope antibiotic |
| ||||||||
Other/unknown | |||||||||
Combinations | |||||||||
|
Baltimore I |
| ||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Hepatitis B (VII) | |||||||||||||||||||||
Multiple/general |
| ||||||||||||||||||||
|
Hepatitis C |
| ||||||||
---|---|---|---|---|---|---|---|---|---|
Hepatitis D | |||||||||
Picornavirus | |||||||||
Anti- influenza agents | |||||||||
Multiple/general |
| ||||||||
|
Capsid inhibitors | |||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Entry/fusion inhibitors ( Discovery and development) | |||||||||||||
Integrase inhibitors (Integrase strand transfer inhibitors (INSTI)) | |||||||||||||
Maturation inhibitors | |||||||||||||
Protease Inhibitors (PI) ( Discovery and development) |
| ||||||||||||
Reverse-transcriptase inhibitors (RTIs) |
| ||||||||||||
Combined formulations |
| ||||||||||||
Pharmacokinetic boosters | |||||||||||||
Experimental agents |
| ||||||||||||
|
Immune sera and immunoglobulins (
J06) | |||||
---|---|---|---|---|---|
Polyclonal antibodies |
| ||||
Monoclonal antibodies |
Development | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Classes | |||||||||||
Administration | |||||||||||
Vaccines |
| ||||||||||
Inventors/ researchers | |||||||||||
Controversy | |||||||||||
Related | |||||||||||
|